| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥941.9B | ¥906.5B | +3.9% |
| Operating Income | ¥167.1B | ¥183.7B | -9.0% |
| Profit Before Tax | ¥159.7B | ¥179.8B | -11.2% |
| Net Income | ¥114.0B | ¥136.2B | -16.3% |
| ROE | 12.9% | 16.7% | - |
FY2025 consolidated results showed Revenue of 94.19 billion yen (YoY +3.9%), Operating Income of 16.71 billion yen (YoY -9.0%), and Net Income of 11.40 billion yen (YoY -16.3%). Despite top-line growth, profitability declined substantially. Gross profit margin remained robust at 56.1%, but SG&A expenses of 35.54 billion yen pressured operating margins. Operating cash flow of 9.39 billion yen represented only 0.82x net income, indicating quality concerns related to working capital expansion. Free cash flow totaled 2.76 billion yen after capital expenditure of 5.83 billion yen. The company maintained aggressive shareholder returns with dividends of 2.83 billion yen and share buybacks of 4.04 billion yen, totaling 6.87 billion yen in capital distribution. Total assets reached 185.21 billion yen with equity of 88.40 billion yen, yielding an equity ratio of 47.7%. Goodwill of 51.88 billion yen represents 58.7% of total equity, presenting material impairment risk.
Revenue increased 3.9% to 94.19 billion yen, driven by ongoing demand for scientific instruments despite challenging market conditions. Cost of sales rose 16.9% to 41.31 billion yen, compressing gross profit margin slightly but maintaining a healthy 56.1% level. The gross profit decline from 55.30 billion yen to 52.88 billion yen reflected unfavorable product mix or pricing pressure. SG&A expenses decreased 3.4% to 35.54 billion yen, representing 37.7% of revenue compared to 40.6% in the prior year, indicating improved operational leverage. However, this improvement was insufficient to offset gross margin compression. Other expenses increased significantly to 0.74 billion yen from 0.29 billion yen, representing non-recurring factors that further pressured operating income. Finance costs rose 51.4% to 1.14 billion yen from 0.76 billion yen, reflecting higher interest burden on debt of 55.56 billion yen. Income tax expense increased to 4.57 billion yen despite lower pre-tax profit, resulting in an effective tax rate of 28.6% compared to 24.3% in the prior year. The gap between operating income of 16.71 billion yen and ordinary income approximation of 15.97 billion yen (pre-tax profit) represents a net non-operating loss of 0.74 billion yen, primarily from elevated finance costs. This exemplifies a revenue up/profit down pattern, where modest revenue growth was overwhelmed by cost structure deterioration and financing burden.
The company operates a single segment of scientific instrument manufacturing and sales, with no segment-level performance breakdown disclosed.
[Profitability] ROE of 13.4% demonstrates solid return generation on shareholder capital. Operating margin contracted to 17.7% from the prior year's higher level, reflecting the operating income decline despite revenue growth. Net profit margin of 12.1% remained healthy but declined from 15.0% in the prior period. The DuPont analysis reveals ROE drivers: net margin 12.1%, asset turnover 0.509x, and financial leverage 2.10x, yielding a calculated ROE of approximately 12.9%. The primary deterioration factor was net margin compression driven by gross profit reduction and elevated finance costs. [Cash Quality] Cash and equivalents of 24.28 billion yen declined from 27.99 billion yen, covering short-term borrowings of 6.86 billion yen 3.54 times, indicating adequate liquidity buffer. Operating cash flow of 9.39 billion yen relative to net income of 11.40 billion yen produces a concerning 0.82x ratio, signaling cash conversion challenges tied to working capital expansion. [Investment Efficiency] Asset turnover of 0.509x reflects capital-intensive operations with substantial fixed assets and goodwill. Trade receivables surged 40.2% to 28.44 billion yen, substantially outpacing revenue growth of 3.9%, indicating extended collection periods or sales concentration in the period close. Inventories remained elevated at 20.88 billion yen, representing potential obsolescence risk or build for anticipated demand. [Financial Health] Equity ratio of 47.7% positions the company in moderate financial stability territory. Total borrowings of 55.56 billion yen yield a debt-to-equity ratio of 0.63x, representing manageable leverage. Goodwill of 51.88 billion yen comprises 58.7% of total equity, presenting material capital impairment risk if acquired businesses underperform. Lease liabilities totaled 6.61 billion yen across current and non-current portions. Retained earnings of 36.46 billion yen increased 41.7% from 25.74 billion yen, demonstrating profit accumulation despite aggressive distributions.
Operating cash flow of 9.39 billion yen represented 0.82x net income of 11.40 billion yen, indicating earnings quality concerns from working capital deterioration. The operating cash flow subtotal before working capital changes of 14.72 billion yen was substantially reduced by trade receivables increase of 8.01 billion yen, signaling collection delays that outpaced revenue growth. Trade payables increased 1.84 billion yen, providing modest working capital relief, but contract liabilities decreased 1.29 billion yen, reducing advance payment cushion. Income taxes paid of 4.65 billion yen and interest paid of 1.10 billion yen represented material cash outflows. Investing cash flow of negative 6.63 billion yen reflected capital expenditure of 5.83 billion yen, demonstrating continued investment in productive capacity. Free cash flow of 2.76 billion yen fell substantially short of total shareholder distributions. Financing cash flow of negative 6.60 billion yen comprised dividends of 2.83 billion yen, share buybacks of 4.04 billion yen totaling 6.87 billion yen in distributions, alongside long-term debt repayment of 4.00 billion yen offset partially by new borrowings of 4.17 billion yen. The net cash decline of 3.72 billion yen reflected capital distributions exceeding operational cash generation. Lease payments of 1.21 billion yen represented ongoing facility and equipment commitments.
Operating income of 16.71 billion yen compared to pre-tax profit of 15.97 billion yen indicates net non-operating loss of approximately 0.74 billion yen. This comprises finance costs of 1.14 billion yen partially offset by finance income of 0.41 billion yen, yielding net finance cost of 0.73 billion yen. Other expenses of 0.74 billion yen exceeded other income of 0.11 billion yen by 0.63 billion yen, representing non-recurring factors or operational adjustments. Non-operating items represented 0.8% of revenue as a net burden, modest in relative terms but material in absolute impact given profit compression. Operating cash flow of 9.39 billion yen fell short of net income of 11.40 billion yen, producing a concerning 0.82x ratio that signals working capital consumption rather than healthy cash generation. The primary quality concern stems from trade receivables expansion of 8.01 billion yen within operating cash flow, indicating either extended payment terms, customer credit deterioration, or period-end sales concentration. Earnings quality warrants monitoring as cash conversion remains impaired.
Full-year forecast projects Revenue of 101.0 billion yen (YoY +16.1%), Operating Income of 19.4 billion yen (YoY +16.1%), and Net Income of 12.5 billion yen (YoY +9.6%). Current period results represent 93.3% progress rate against revenue guidance and 86.1% against operating income guidance, indicating strong likelihood of exceeding targets if seasonal patterns hold. The operating income guidance implies substantial second-half improvement to offset current period shortfall. Contract liabilities of 4.96 billion yen declined from 6.43 billion yen, representing advance payments for future delivery. The Backlog-to-Revenue ratio of 5.3% (contract liabilities relative to annual revenue) provides limited forward revenue visibility, typical for shorter-cycle businesses. Management guidance assumes operational improvements and potential non-recurring benefit reversals in the remainder of the fiscal year. The aggressive revenue growth forecast of 16.1% substantially exceeds the 3.9% achieved in the current period, requiring acceleration in the final period.
Annual dividend of 9.50 yen per share is forecast, with interim dividends already paid. Based on forecast EPS of 55.27 yen, the payout ratio stands at 17.2%, representing conservative distribution relative to earnings. Actual dividend payments of 2.83 billion yen in the current period were supplemented by share buybacks of 4.04 billion yen, totaling 6.87 billion yen in distributions. The combined total return ratio approximates 60.3% relative to net income of 11.40 billion yen, demonstrating aggressive capital return policy. This aggressive posture contrasts with free cash flow of only 2.76 billion yen, indicating distributions exceeded organic cash generation. Treasury stock increased substantially to 4.04 billion yen from virtually nil, reflecting the buyback execution. The company issued new shares worth 1.32 billion yen from stock option exercises, partially offsetting buyback impact. The capital allocation prioritizes immediate shareholder returns over balance sheet strengthening, appropriate given adequate equity ratio but requiring monitoring against cash generation sustainability.
Working capital deterioration presents the most immediate risk, with trade receivables increasing 40.2% far exceeding revenue growth of 3.9%, indicating collection period extension or customer credit concerns. Days Sales Outstanding likely expanded materially, consuming cash and potentially signaling customer financial stress. Inventory of 20.88 billion yen remains elevated at approximately 22.2% of revenue, presenting obsolescence risk if demand softens. Combined working capital expansion drove operating cash flow to only 0.82x net income, an unsustainable quality level that constrains financial flexibility. Goodwill of 51.88 billion yen representing 58.7% of equity presents material impairment risk if acquired scientific instrument businesses underperform amid market softness. Prior acquisitions often carry optimistic assumptions that may not materialize, and any impairment would directly reduce equity. Cost structure pressure is evident as gross margin compressed despite high absolute levels, with SG&A at 37.7% of revenue leaving limited operating leverage. Finance costs rose 51.4% to 1.14 billion yen on debt of 55.56 billion yen, implying average cost approaching 2.1% and interest rate sensitivity. Total shareholder distributions of 6.87 billion yen exceeded free cash flow of 2.76 billion yen by 4.11 billion yen, funded by working capital drawdown and cash reserves decline of 3.72 billion yen. Sustaining this distribution level requires operating cash flow improvement or debt increase.
[Industry Position] (Reference - Proprietary Analysis)
Rigaku Holdings operates in the scientific instruments manufacturing industry, characterized by high technological barriers, long customer relationships, and significant R&D investment requirements. The company's ROE of 13.4% and operating margin of 17.7% position it as a profitable player within the industry. The equity ratio of 47.7% reflects moderate financial stability typical of capital-intensive manufacturing operations with acquisition history. Profitability metrics demonstrate the company's ability to generate returns on shareholder capital despite challenging market conditions and profit compression in the current period. The operating margin of 17.7%, while declining from prior year, suggests differentiated technology and customer value proposition relative to commodity scientific equipment suppliers. However, the working capital efficiency deterioration, evidenced by receivables increasing 40.2% against revenue growth of only 3.9%, indicates potential competitive pressure on payment terms or customer quality concerns relative to more efficient industry peers. Goodwill representing 58.7% of equity exceeds typical industry norms and reflects aggressive acquisition strategy, presenting both growth opportunity and impairment risk concentration. The company's total shareholder return policy with combined payout and buybacks exceeding free cash flow demonstrates confidence but also limits balance sheet flexibility relative to more conservative peers who prioritize debt reduction or cash accumulation in uncertain environments.
Revenue growth of 3.9% with aggressive full-year guidance of 16.1% indicates management confidence in demand recovery or new product cycles, though execution risk remains given current period shortfall in operating profit relative to revenue growth. The structural profitability pressure from gross margin compression and elevated finance costs represents a trend requiring reversal through product mix improvement, pricing power recovery, or cost reduction initiatives. Working capital management emerged as a critical concern with trade receivables expanding 40.2% far exceeding revenue growth, signaling either deliberate terms extension to support sales or involuntary collection deterioration. The operating cash flow to net income ratio of 0.82x indicates unsustainable cash conversion quality that must improve to support current capital allocation priorities. Shareholder return policy demonstrates aggressive capital deployment with total distributions of 6.87 billion yen exceeding free cash flow of 2.76 billion yen, sustainable only through working capital improvement or debt increase. The payout ratio of 17.2% on forecast earnings appears conservative, but the total return ratio including buybacks of approximately 60% reflects commitment to immediate returns over balance sheet fortification. Goodwill concentration at 58.7% of equity represents a structural vulnerability requiring vigilant monitoring of acquired business performance and potential impairment triggers. The company operates in a niche scientific instruments market with technological differentiation enabling mid-teens operating margins despite capital intensity, positioning it favorably relative to commodity equipment suppliers but vulnerably relative to software-centric scientific solution providers with superior cash generation.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.